New drug combo for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with prostate cancer that has spread to other parts of the body (bone or other organs).
- You have not yet received chemotherapy or other strong treatments for this stage of your cancer (called metastatic castration-sensitive, or mCSPC).
- You are in good enough health to do your usual daily activities (ECOG score 0 or 1).
- You do not have a serious heart condition, known brain metastases, or active thoughts of self-harm.
- You are not allergic to the study drugs or currently taking medications that strongly affect an important liver enzyme (CYP3A4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a new combination of two medicines for advanced prostate cancer that has spread and is no longer responding to current hormone therapy. The goal is to see if adding the experimental drug mevrometostat to enzalutamide helps control the cancer better.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
Hear when a new Hormone Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.